Cyrill Wolf
YOU?
Author Swipe
A single-center single-shot devices experience for pulmonary vein isolation Open
Funding Acknowledgements Type of funding sources: None. Background Pulmonary vein isolation (PVI) is the gold standard for treatment of atrial fibrillation (AF). Single-shot devices have been introduced to provide a faster and more simplif…
sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation Open
Background We investigated the impact of the soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio to predict short-term risk of preeclampsia on clinical utility and healthcare resource utilisation using real-wor…
View article: Cost effectiveness of the sFlt1/PlGF ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States
Cost effectiveness of the sFlt1/PlGF ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States Open
Adopting the sFlt1/PlGF ratio test as an adjunct to clinical criteria improves the assessment of risk in women presenting with suspicion of preeclampsia and has the potential to safely reduce unnecessary admissions and save costs.
Real‐world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non‐valvular atrial fibrillation patients in England Open
Rationale, Aims, and Objectives Several novel oral anticoagulants (NOACs) are licensed for atrial fibrillation (AF) treatment in the United Kingdom. We describe the incidence and mortality from ischaemic stroke and major bleeding in non‐va…
View article: Diagnostic utility of angiogenic biomarkers in pregnant women with suspected preeclampsia: A health economics review
Diagnostic utility of angiogenic biomarkers in pregnant women with suspected preeclampsia: A health economics review Open
Preeclampsia is a major cause of morbidity and mortality, can be difficult to diagnose, and is associated with significant healthcare costs. The prediction, diagnosis and prognosis of preeclampsia have depended on repeated assessment of wo…
Economic assessment of the use of the sFlt-1/PlGF ratio test to predict preeclampsia in Germany Open
The sFlt-1/PlGF ratio test is likely to reduce unnecessary hospitalization of women with a low risk of developing preeclampsia, and identify those at high risk to ensure appropriate management. Even within the restrictions of the DRG syste…
P288National prescribing and adverse event rates of patients at risk of stroke with non-valvular AF from CPRD linked database: does “big data” reflect clinical trials and identify areas for improvement? Open
yses were conducted to test the robustness of the findings, including a highdimensional PS (hdPS) analysis to account for empirically identified proxies of unmeasured confounders Results: By the end of the study period, the analyses includ…
Economic evaluation of sFlt-1/PlGF ratio test in pre-eclampsia prediction and diagnosis in two Brazilian hospitals Open
The sFlt-1/PlGF ratio test has the potential to improve clinical decision-making and allocation of scarce resources by reducing unnecessary hospitalization of women at low risk of developing pre-eclampsia, and ensuring that women at higher…
sFlt‐1/PlGF ratio test for pre‐eclampsia: an economic assessment for the UK Open
Objectives To assess the economic impact of introducing into clinical practice in the UK the soluble fms‐like tyrosine kinase (sFlt‐1) to placental growth factor (PlGF) ratio test for guiding the management of pre‐eclampsia. Methods We use…